<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00409305</url>
  </required_header>
  <id_info>
    <org_study_id>BET201</org_study_id>
    <nct_id>NCT00409305</nct_id>
  </id_info>
  <brief_title>The Effect of Betahistine on Body Weight in Obese Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Betahistine on Body Weight in Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OBEcure Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OBEcure Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effect that betahistine has on body weight in
      obese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To examine the effect of betahistine on body weight in obese subjects</measure>
  </primary_outcome>
  <enrollment>280</enrollment>
  <condition>Obesity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betahistine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dietary counseling</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent;

          -  Male or female subjects 18 to 65 years of age;

          -  Is obese with a BMI greater than or equal to 30 kg/m2 to less than or equal to 40
             kg/m2;

          -  Has been obese for at least 1 year prior to screening; and

          -  If female, is nonlactating, has a negative urine pregnancy test result, and does not
             plan on becoming pregnant during the study, or not of childbearing potential
             (hysterectomy or tubal ligation at least 6 months prior to randomization or
             post-menopausal for 1 year); if of childbearing potential (including peri-menopausal
             women who have had a menstrual period within 1 year) must practice or be willing to
             continue to practice appropriate birth control (such as implants, injectables, oral
             contraceptives, some intrauterine contraceptive devices, sexual abstinence, tubal
             ligation, or a vasectomized partner) during the entire study duration.

        Exclusion Criteria:

          -  Has obesity of known endocrine origin (e.g., Cushing's disease, Addison's disease,
             hypothalamic tumor);

          -  Has a medical history (e.g., morbid childhood obesity) and/or physical characteristics
             (e.g., polydactyly) suggestive of genetic obesity (e.g., ob/ob genotype) or
             syndromatic obesity (e.g., Prader-Willi syndrome, Bardet Biedl syndrome);

          -  Previous surgical procedures for weight loss;

          -  Has had liposuction within 1 year before screening or is planning to have liposuction
             during the study;

          -  History of bulimia or evidence of laxative abuse;

          -  Has had a body weight loss of &gt;4 kg in the 90 days prior to screening;

          -  Has taken drugs capable of influencing body weight 30 days prior to screening;

          -  Has recently started or plans on starting a smoking cessation program;

          -  Has had a major change in daily physical activity (e.g., initiation of an exercise
             program) or started a weight loss program within 90 days prior to screening;

          -  Is unwilling or unable to participate in a dietary program as part of the study;

          -  Is &lt;80% compliant with study medication in the single-blind placebo run-in period;

          -  Has a clinically significant history or presence of any of the following conditions:

          -  Active or past history of cardiovascular or cerebrovascular disease including unstable
             angina, myocardial infarction, transient ischemic attacks/stroke, clinically
             significant arrhythmia, congestive heart failure, or cardiac valve abnormalities;

          -  Liver disease (irrespective of transaminase concentrations);

          -  Pheochromocytoma;

          -  Porphyria;

          -  Type 1 diabetes mellitus;

          -  Type 2 diabetes mellitus on treatment other than metformin monotherapy and/or diet
             with HbA1c less than or equal to 8%;

          -  Severe type 2 diabetes with history of ketoacidosis or diabetic ulcers, or presence of
             retinopathy, neuropathy, or nephropathy;

          -  Renal insufficiency defined as a serum creatinine greater than or equal to 1.5 mg/dL
             (133 µmol/L) at screening;

          -  Malignant disease within 5 years of screening;

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;2 x ULN;

          -  Thyroid-stimulating hormone (TSH) outside of the normal range;

          -  Plans on having any surgery (elective or otherwise) during the course of the study;

          -  Has uncontrolled hypertension (sitting blood pressure &gt;160/95 mmHg at screening or
             randomization), uncontrolled hyperlipidemia (triglycerides [TG] greater than or equal
             to 400 mg/dL or low-density lipoprotein cholesterol [LDL-C] &gt;160 mg/dL), or
             uncontrolled diabetes (HbA1c &gt;8%);

          -  History of asthma;

          -  History of peptic ulcers;

          -  History of HIV;

          -  History of undiagnosed allergy, severe allergy, or drug allergy, including history of
             anaphylaxis, angioedema, bronchospasm, or urticaria;

          -  Has clinical laboratory test values (chemistry, hematology, or urinalysis) judged to
             be clinically significant by the investigator;

          -  Has a physical examination or electrocardiogram (ECG) with significant abnormalities,
             as judged by the investigator;

          -  Currently abuses drugs or alcohol or has a history of abuse that in the investigator's
             opinion could cause the subject to be noncompliant with study procedures;

          -  Has hypersensitivity to betahistine;

          -  Has psychiatric or neurological disorders requiring chronic medications (e.g.,
             antidepressants), subjects are to be unlikely to have a major depressive episode
             (score of lees than or equal to 8) on The Harvard Department of Psychiatry and
             National Depression Screening Day Scale (THE HANDS) (See Appendix E);

          -  Chronic or as needed use of antihistamines;

          -  Has not been on a stable treatment regimen with any of the following medications for a
             minimum of 90 days prior to screening:

          -  Hormone replacement therapy;

          -  Oral contraceptives;

          -  Antihypertensive agents;

          -  Metformin;

          -  Lipid-lowering agents; or

          -  Thyroid replacement therapy;

          -  Has been treated over the past 60 days, is currently treated, or is expected to
             require or undergo treatment with any of the following excluded medications;

          -  All prescription or over-the-counter agents taken for the purpose of weight reduction,
             including (but not limited to) the following anti obesity agents:

          -  Prescription drugs such as orlistat, sibutramine, and phentermine; or

          -  Over-the-counter antiobesity agents (e.g., herbal supplements or other alternative
             remedies such as Cortislim, Dexatrim, Acutrim);

          -  Psychotropic/neurological agents including the following:

          -  Antipsychotic agents (e.g., olanzapine, clozapine, risperidol, lithium, etc.).

          -  Antiepileptic agents (e.g., Topamax®, Zonegran®, valproate, carbamazepine); or

          -  Antidepressant agents including the following: monoamine oxidase inhibitors, bupropion
             (Wellbutrin®, Zyban®), tricyclic antidepressants, and tetracyclic antidepressants; and
             selective serotonin reuptake inhibitors (e.g., Prozac®, Paxil®, Zoloft®, etc.);

          -  Systemic steroids administered by oral, intravenous, or intramuscular route;

          -  Drugs that directly affect gastrointestinal motility (e.g., Reglan® and Propulsid®,
             and chronic [taken for more than 10 days within a 6-month period] macrolide
             antibiotics such as erythromycin and newer derivatives);

          -  Calcitonin (e.g., Miacalcin®);

          -  Insulin;

          -  Exenatide (Byetta);

          -  Sulfonylureas (e.g., Diamicron, Amaryl, Glucotrol, Micronase); or Meglitinides (e.g.,
             Starlix, Prandin)

          -  Has received any investigational drug within 90 days of screening;

          -  Receipt of any investigational treatment (drug or device) within 90 days prior to
             screening;

          -  Is an immediate family member of personnel directly affiliated with the study at the
             investigative site, or is personally directly affiliated with the study at the
             investigative site; or

          -  Is employed by OBEcure Ltd.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Ahmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance CRU, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Louis Aronne, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Comprehensive Weight Control Program</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harold Bays, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>L-Marc Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norman Fishman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes &amp; Endocrinology Specialists</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ken Fujioka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Clinic, Nutrition Metabolic Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Geohas, MD</last_name>
    <role>Study Director</role>
    <affiliation>Radiant Research, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank Greenway, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pennington Biodmedical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dean Kereiakes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lindner Clinical Trial Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diane Krieger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Miami Research Associates, Nutrition Division</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Kushner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCCR</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Moretto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>American Health Network</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Monica Pierson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherwyn Schwartz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes &amp; Glandular Disease Research Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diane Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CSRA Partners in Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip Toth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Midwest Institute for Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mervyn Weerasinghe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rochester Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Weinstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diablo Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lisa Wright, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cahaba Research, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Zavoral, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiant Research, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nir Barak, MD</last_name>
    <role>Study Director</role>
    <affiliation>OBEcure Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yaffa Beck, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>OBEcure Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ami Eyal, MD</last_name>
    <role>Study Chair</role>
    <affiliation>OBEcure Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cahaba Research, Inc.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic, Nutrition Metabolic Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research, Inc.</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates, Inc., Nutrition Division</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSRA Partners in Health, Inc.</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCCR</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Network</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Institute for Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L-MARC Research Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes &amp; Endocrinology Specialists</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Weight Control Program</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lindner Clinical Trial Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance CRU, Inc.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes &amp; Glandular Disease Research Associates, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2006</study_first_submitted>
  <study_first_submitted_qc>December 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2006</study_first_posted>
  <last_update_submitted>April 20, 2015</last_update_submitted>
  <last_update_submitted_qc>April 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2015</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betahistine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

